Exhibit 2.

Prevalence of antipsychotic use in children (2–17 years) enrolled in Medicaid, 2008–2016 ^a,b

Year	Children with antipsychotic use, Full sample		Children in foster carec		Children not in foster care
	No.	%	No.	%	No.	%
2008	348,253	2.31	68,657	10.89	279,596	1.93
2009	366,072	2.20	66,578	10.86	299,494	1.87
2010	374,715	2.10	62,332	10.40	312,383	1.81
2011	385,357	2.04	58,972	10.32	326,385	1.78
2012	392,168	1.98	61,582	10.05	330,586	1.72
2013	395,424	1.95	61,382	9.81	334,042	1.70
2014	372,037	1.70	50,535	9.15	321,502	1.51
2015	358,904	1.52	35,389	8.88	323,515	1.39
2016	323,861	1.32	37,369	7.09	286,492	1.19

SOURCE [Authors’ analysis of data from CMS Medicaid data from 2008–2016]

^aAntipsychotics included first-generation antipsychotic medications: chlorpromazine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, perphenazine, pimozide, promazine, thioridazine, thiothixene, trifluoperazine, triflupromazine; and second-generation antipsychotic medications: aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone; Combination products olanzapine/fluoxetine and perphenazine/amitriptyline were included.

^bMedicaid data from 45 states (excluded states include Arizona, Delaware, Nevada, Oregon, Rhode Island, along with the District of Columbia); For 2015 Maryland data, we required only 11 months of enrollment given missing March 2015 monthly enrollment indicator

^cFoster care status was based on Medicaid eligibility in December of that calendar year